ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality

被引:11
|
作者
Dun, Yiting [1 ]
Huang, Gang [1 ,2 ]
Liu, Jianjun [1 ]
Wei, Weijun [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Inst Clin Nucl Med,Dept Nucl Med, Shanghai 200217, Peoples R China
[2] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China
基金
中国国家自然科学基金;
关键词
ImmunoPET; Hematological malignancies; Antibody; Lymphoma; Leukemia; Multiple myeloma; POSITRON-EMISSION-TOMOGRAPHY; RECEPTOR CXCR4 EXPRESSION; TRANSGENIC MOUSE MODEL; RADIATION-DOSIMETRY; MONOCLONAL-ANTIBODY; MULTIPLE-MYELOMA; IN-VIVO; B-CELLS; LYMPHOMA; THERAPY;
D O I
10.1016/j.drudis.2021.11.019
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immuno-positron emission tomography (immunoPET) imaging is a paradigm-shifting imaging technique for whole-body and all-lesion tumor detection, based on the combined specificity of tumor-targeting vectors [e.g., monoclonal antibodies (mAbs), nanobodies, and bispecific antibodies] and the sensitivity of PET imaging. By noninvasively, comprehensively, and serially revealing heterogeneous tumor antigen expression, immunoPET imaging is gradually improving the theranostic prospects for hematological malignancies. In this review, we summarize the available literature regarding immunoPET in imaging hematological malignancies. We also highlight the pros and cons of current conjugation strategies, and modular chemistry that can be leveraged to develop novel immunoPET probes for hematological malignancies. Lastly, we discuss the use of immunoPET imaging in guiding antibody drug development.
引用
收藏
页码:1196 / 1203
页数:8
相关论文
共 50 条
  • [21] Imaging Techniques and Clinical Application of the Marrow-Blood Barrier in Hematological Malignancies
    Zhang, Jianling
    Huang, Qianqian
    Bian, Wenjin
    Wang, Jun
    Guan, Haonan
    Niu, Jinliang
    DIAGNOSTICS, 2024, 14 (01)
  • [22] Cardiac Hematological Malignancies: Typical Growth Patterns, Imaging Features, and Clinical Outcome
    Voigt, Peter
    Wienbeck, Susanne
    Weber, Marc-Andre
    Oyama-Manabe, Noriko
    Beimler, Maximilian
    Schob, Stefan
    Kahn, Thomas
    Meyer, Hans Jonas
    Randaxhe, Jan Frieso
    Surov, Alexey
    ANGIOLOGY, 2018, 69 (02) : 170 - 176
  • [23] CLINICAL IMPLICATIONS OF CYTOGENETICS IN HEMATOLOGICAL MALIGNANCIES
    Panani, Anna D.
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3590 - 3590
  • [24] Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies
    Patel, Anand A.
    Cahill, Kirk
    Saygin, Caner
    Odenike, Olatoyosi
    BLOOD ADVANCES, 2021, 5 (08) : 2264 - 2271
  • [25] IMAGING OF PULMONARY INFECTIOUS COMPLICATIONS IN HEMATOLOGICAL MALIGNANCIES
    Federica, C.
    Armenio, S.
    Angela, F.
    Lidia, S.
    Francesca, I.
    Raffaele, P.
    Daniela, B.
    Nicola, C.
    Roberto, G.
    HAEMATOLOGICA, 2014, 99 : 753 - 754
  • [26] FDG-PET imaging in hematological malignancies
    Valls, L.
    Badve, C.
    Avril, S.
    Herrmann, K.
    Faulhaber, P.
    O'Donnell, J.
    Avril, N.
    BLOOD REVIEWS, 2016, 30 (04) : 317 - 331
  • [27] Hematological Cardiac Malignancies - Typical Imaging Patterns
    Meyer, Hans Jonas
    Wienbeck, Susanne
    Surov, Alexey
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2019, 191 (09): : 787 - 789
  • [28] From promise to reality
    ASEE PRISM, 3 (30):
  • [29] Nanobody targeting CD70 for immunoPET imaging in preclinical tumor models
    Elvas, F.
    Dewulf, J.
    Flieswasser, T.
    Delahaye, T.
    Vanghestel, C.
    Miranda, A.
    Jacobs, J.
    Smits, E.
    Van den Wyngaert, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S281 - S281
  • [30] Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus Reality
    Sellar, Rob
    Losman, Julie-Aurore
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 565 - +